An Erupting Landscape: Nosocomial Pneumonia in the Age of Resistance

Supported by an educational grant from Ortho McNeil
Estimated running time: 1.5 hours
Credit Valid: March 2008-March 2009

Learning Objectives
At the conclusion of this activity, participants should be able to:

• Discuss emerging epidemiological trends among nosocomial Gramnegative bacilli
• Determine the rationale of antimicrobial dosing strategies to optimize clinical outcomes and prevent resistance development
• Identify viable therapeutic options for these difficult-to-treat infections

Target Audience
This continuing medical education offering is intended to meet the needs of any healthcare provider involved in the care of critically ill patients, including advance practice nurses, critical care nurses, intensivists, critical care fellows, anesthesiologists, internists, surgeons, cardiologists, pulmonologists, emergency medicine practitioners, neurologists, and respiratory therapists.

Obtaining Credit
Click here to complete the evaluation and credit verification.
Upon receipt, your certificate will be sent to you within 30 days.
If you have any questions, please contact the Continuing Education Department at 847-827-6869 or at education@sccm.org

Physicians/Physician Assistants
SCCM designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim credit commensurate with the extent of their participation in the activity.

Nurses
SCCM is approved by the California Board of Registered Nursing, Provider No. 8181, and the American Association of Critical-care Nurses (#00013930) and approves this activity for 1.5 contact hours.

Pharmacists
SCCM is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This activity will provide 1.5 continuing education hours. (236-000-08-150-H01-P)


Faculty Disclosure Statement

Faculty reported the following disclosures for this activity:

Michael S. Niederman, MD, FCCM
Winthrop University Hospital
Mineola, New York, USA
Advisory Board: Johnson & Johnson, Pfizer, Schering, Merck, AstraZeneca, Theravance, Nektar

David Nicolau, PharmD
Hartford Hospital
Hartford, Connecticut, USA
Research Grant, Speakers Bureau: AstraZeneca, Merck, Johnson & Johnson, Wyeth, Cubist, Vertex, Astellas, Pfizer

Donald E. Craven, MD
Tufts University School of Medicine
Lahey Clinic Medical Center
Burlington, Massachusetts, USA
Honoraria, Speakers Bureau: Pfizer, Elan, Sanofi Pasteur, Wyeth, Arpida, Cubist, Merck; Research Grants: Bard Data
and Safety Monitoring Board, Johnson & Johnson; Consultant: Wyeth, Bayer, Nektar, Cubist